Pharmacology of Antiretroviral Agents An Emphasis on Drug ...

References1. Centers for Disease Control and Prevention [Internet]. Atlanta: Division <strong>of</strong> HIV/AIDS Prevention; [updated 16 July 2012; cited 15 September 2012]. Available from:http://www.cdc.gov/hiv/topics/surveillance/resources/slides/trends/index.htmUNAIDS.2. UNAIDS. World AIDS Day Report; 2011/ Available from:http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2216_WorldAIDSday_report_2011_en.pdf3. Luther VP, Wilken AL. HIV Infection in Older Adults Clin Geriatr Med. 2007;23:567-83.4. Centers for Disease Control and Prevention [Internet]. Atlanta: Division <strong>of</strong> HIV/AIDS Prevention; [updated 16 February 2011; cited 15 September 2012]. Available from:http://www.cdc.gov/hiv/surveillance/resources/reports/2009report/5. Centers for Disease Control and Prevention [Internet]. Atlanta: Division <strong>of</strong> HIV/IDS Prevention; [updated 10 August 2011; cited 15 September 2012]. Available from:http://www.cdc.gov/hiv/topics/surveillance/resources/slides/incidence/index.htm6. Hogg R, Samji J, Modur S, Cescon A, Modur, S,Napravnik S, Martin J, et al. Temporal Changes in Life Expectancy <strong>of</strong> HIV+ Individuals: North America. Paper #137. 2012. Conference onRetroviruses and Opportunistic Infections (CROI). Seattle, WA, USA7. Pomerantz RJ and Horn DL. 20 Years <strong>of</strong> Therapy for HIV-1 Infection. Nat Med 2003; 9:867-8738. Volberding P and Deeks S. <strong><strong>An</strong>tiretroviral</strong> Therapy and Management <strong>of</strong> HIV Infection. Lancet. 2010;376:49-62.9. LaBonte J , Lebbos J, and Kirkpatrick P. Nat Rev Drug Disc. 2003;2:345-6.10. Parker, K. (2006). GOODMAN & GILMAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTICS (11th). New York, NY; McGraw-Hill. Retrieved September 7, 2010 from http://0-www.r2library.com.ilsprod.lib.neu.edu/marc_frame.aspx?ResourceID=29411. Brunton, L. & Lazo, J. & Parker, K. (2006). GOODMAN & GILMAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTICS (11th). New York, NY; McGraw-Hill. Retrieved September7, 2010 from http://0-www.r2library.com.ilsprod.lib.neu.edu/marc_frame.aspx?ResourceID=29412. Pommier Y, Johnson AA and Marchand C. Integrase Inhibitors to Treat HIV/AIDS. Nat Rev Drug Discov. 2005 Mar;4(3):236-48.13. Panel on <strong><strong>An</strong>tiretroviral</strong> Guidelines for Adults and Adolescents. Guidelines for the use <strong>of</strong> antiretroviral agents in HIV-1-infected adults and adolescents. Department <strong>of</strong> Health and HumanServices. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Section accessed [2012 Sept 15]14. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Gunthard HF, Hammer SH, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA.<strong><strong>An</strong>tiretroviral</strong> Treatment <strong>of</strong> Adult HIV Infection: 2012 Recommendations <strong>of</strong> the International <strong>An</strong>tiviral Society–USA Panel. JAMA. 2012;308(4):387-402.15. Piscitelli SC and Gallicano KD. Interactions Among Drugs for HIV and Opportunistic Infections. N Engl J Med 2001;344:984-96.16. Horn JR, Hansten PD. Drug transporters: the final frontier for drug interactions. Pharmacy Times ; cited 15 September 2012. Available from:http://www.pharmacytimes.com/publications/issue/2008/2008-12/2008-12-847417. Mangoni AA and Jackson SHD. Age-related Changes in Pharmacokinetics and Pharmacodynamics. Br J Clin Pharmacol. 2003;57:6-14.18. Summary Report for the Human Immunodeficiency Virus and Aging Consensus Project: Treatment Strategies for Clinicians Managing Older Individuals with the HumanImmunodeficiency Virus. J Am Geriatr Soc 2012;60:974-9.19. Marzolini C, Back D, Weber R, et al. Ageing with HIV: medication use and risk for potential drug-drug interactions. J <strong>An</strong>rimicrob Chemother 2011; 66:2107-11.20. Aspden P, Wolcott J, Bootman JL, Cronenwett LR, editors. Preventing Medication Errors: Quality ChasmSeries. Committee on Identifying and Preventing Medication Errors. 2007.Available from: http://psnet.ahrq.gov/resource.aspx?resourceID=405321. Rastegar DA, Knight AM, and Monolakis JS. <strong><strong>An</strong>tiretroviral</strong> Medication Errors Among Hospitalized Patients with HIV Infection. Clin Infect Dis 2006;43:933-8.22. Snyder AM, Klinker K, Orrick JJ, et al. <strong>An</strong> In-depth <strong>An</strong>alysis <strong>of</strong> Medication Errors in Hospitalized Patients with HIV. <strong>An</strong>n Pharmacother 2011;45:459-68.23. Viiv Health Care. 2012; Selzentry Full Prescribing Information. Available from: http://viivhealthcare.com/~/media/Files/G/GlaxoSmithKline-Plc/pdfs/us_selzentry.pdf24. Fitchenbaum CJ and Gerber JG. Interactions between antiretroviral drugs and drugs used for the therapy <strong>of</strong> metabolic complications encountered during HIV Infection. ClinPharmacokinet 2002;41:1195-1211.25. Kempf DJ et al. Pharmacokinetic Boosting <strong>of</strong> VX-950 and SCH 503034, inhibitors <strong>of</strong> HCV Protease, by codosing with ritonavir. 41 st Meeting <strong>of</strong> the European Association for the study <strong>of</strong>liver diseases. Vienna; 2006. Available from: http://www.natap.org/2006/EASL/EASL_13.htm26. Agarwala S, Gray K, Wang Y, et al. Pharmaokinetic Effect <strong>of</strong> Omperazole on Atazanavir with Ritonavir in Healthy Subjects. 12th Conference on Retroviruses and Opportunistic Infections(CROI) Feb 22-25, 2005. Boston, MA. Available from: http://www.medadvocates.org/resources/conferences/croi/12_croi/ataz_115.pdf